[go: up one dir, main page]

DK1448523T3 - Heterocycliske forbindelser samt metoder til anvendelse deraf - Google Patents

Heterocycliske forbindelser samt metoder til anvendelse deraf

Info

Publication number
DK1448523T3
DK1448523T3 DK02787747T DK02787747T DK1448523T3 DK 1448523 T3 DK1448523 T3 DK 1448523T3 DK 02787747 T DK02787747 T DK 02787747T DK 02787747 T DK02787747 T DK 02787747T DK 1448523 T3 DK1448523 T3 DK 1448523T3
Authority
DK
Denmark
Prior art keywords
methods
well
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
DK02787747T
Other languages
English (en)
Inventor
Andrew Thomas Bach
Prasad Koteswara Kapa
George Tien-San Lee
Eric M Loeser
Michael Lloyd Sabio
James Lawrence Stanton
Thalaththani Ralalag Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1448523T3 publication Critical patent/DK1448523T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02787747T 2001-11-21 2002-11-20 Heterocycliske forbindelser samt metoder til anvendelse deraf DK1448523T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33198601P 2001-11-21 2001-11-21
US39690602P 2002-07-18 2002-07-18
PCT/EP2002/013025 WO2003043985A1 (en) 2001-11-21 2002-11-20 Heterocyclic compounds and methods of use

Publications (1)

Publication Number Publication Date
DK1448523T3 true DK1448523T3 (da) 2007-12-27

Family

ID=38460593

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787747T DK1448523T3 (da) 2001-11-21 2002-11-20 Heterocycliske forbindelser samt metoder til anvendelse deraf

Country Status (29)

Country Link
US (4) US7183304B2 (da)
EP (1) EP1448523B1 (da)
JP (2) JP4171700B2 (da)
KR (1) KR100607019B1 (da)
CN (2) CN100429201C (da)
AR (1) AR037655A1 (da)
AT (1) ATE370931T1 (da)
AU (1) AU2002352073B8 (da)
BR (1) BR0214305A (da)
CA (1) CA2463154C (da)
CO (1) CO5590897A2 (da)
DE (1) DE60222006T2 (da)
DK (1) DK1448523T3 (da)
EC (1) ECSP045103A (da)
ES (1) ES2290345T3 (da)
HU (1) HUP0402236A3 (da)
IL (1) IL161258A0 (da)
MX (1) MXPA04004869A (da)
MY (1) MY134965A (da)
NO (1) NO327255B1 (da)
NZ (1) NZ532080A (da)
PE (1) PE20030565A1 (da)
PL (1) PL368637A1 (da)
PT (1) PT1448523E (da)
RU (1) RU2345983C2 (da)
SI (1) SI1448523T1 (da)
TW (1) TW200303742A (da)
WO (1) WO2003043985A1 (da)
ZA (1) ZA200402310B (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520226A (ja) † 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
PT1572196E (pt) * 2002-12-10 2008-11-20 Novartis Ag Combinação de um inibidor da dpp-iv e um composto ppar alfa
DE10300099A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7652061B2 (en) * 2003-05-20 2010-01-26 Novartis A.G. N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
JP2009513523A (ja) * 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
DE10335449A1 (de) * 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
GT200500246A (es) * 2004-09-09 2006-04-17 Combinacion de compuestos organicos
AU2006206682A1 (en) * 2005-01-18 2006-07-27 Novartis Ag Methods of use of dual PPAR agonist compounds and drug delivery devices containing such compounds
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
GT200600302A (es) * 2005-07-13 2007-03-19 Agonistas de ppara/y y procesos de preparación
WO2009018238A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007056497A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2402318A1 (en) 2006-03-31 2012-01-04 Novartis AG DGAT inhibitors
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
US7888351B2 (en) 2006-04-11 2011-02-15 Novartis Ag Organic compounds
MX2008013097A (es) 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
US8498381B2 (en) 2010-10-07 2013-07-30 Moxtek, Inc. Polymer layer on X-ray window
WO2009045915A2 (en) 2007-09-28 2009-04-09 Brigham Young University Carbon nanotube assembly
US9305735B2 (en) 2007-09-28 2016-04-05 Brigham Young University Reinforced polymer x-ray window
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5401544B2 (ja) 2008-07-15 2014-01-29 ノバルティス アーゲー Ｄｇａｔ１阻害剤としてのヘテロアリール誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8247971B1 (en) 2009-03-19 2012-08-21 Moxtek, Inc. Resistively heated small planar filament
CN102448938A (zh) 2009-03-27 2012-05-09 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
EP2413696A4 (en) * 2009-04-03 2012-10-24 Sinai School Medicine COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
CA2774573A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2947073B1 (en) * 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US7983394B2 (en) 2009-12-17 2011-07-19 Moxtek, Inc. Multiple wavelength X-ray source
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8526574B2 (en) 2010-09-24 2013-09-03 Moxtek, Inc. Capacitor AC power coupling across high DC voltage differential
RU2612556C2 (ru) 2010-10-07 2017-03-09 Новартис Аг Новые кристаллические формы натриевой соли(4-{ 4-[5-(6-трифторметил-пиридин-3-иламино) пиридин-2-ил] фенил} циклогексил) уксусной кислоты
CN106117193B (zh) 2011-01-13 2019-09-13 诺华股份有限公司 新的杂环衍生物及其在神经性疾病治疗中的应用
EP2663308A1 (en) 2011-01-13 2013-11-20 Novartis AG Bace-2 inhibitors for the treatment of metabolic disorders
US8804910B1 (en) 2011-01-24 2014-08-12 Moxtek, Inc. Reduced power consumption X-ray source
US8750458B1 (en) 2011-02-17 2014-06-10 Moxtek, Inc. Cold electron number amplifier
US8929515B2 (en) 2011-02-23 2015-01-06 Moxtek, Inc. Multiple-size support for X-ray window
US8792619B2 (en) 2011-03-30 2014-07-29 Moxtek, Inc. X-ray tube with semiconductor coating
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012140596A1 (en) 2011-04-14 2012-10-18 Novartis Ag Glycoside derivatives and uses thereof
US8989354B2 (en) 2011-05-16 2015-03-24 Brigham Young University Carbon composite support structure
US9174412B2 (en) 2011-05-16 2015-11-03 Brigham Young University High strength carbon fiber composite wafers for microfabrication
US9076628B2 (en) 2011-05-16 2015-07-07 Brigham Young University Variable radius taper x-ray window support structure
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
KR20140084146A (ko) 2011-10-13 2014-07-04 노파르티스 아게 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도
ES2606630T3 (es) 2011-11-28 2017-03-24 Novartis Ag Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US8761344B2 (en) 2011-12-29 2014-06-24 Moxtek, Inc. Small x-ray tube with electron beam control optics
AP3592A (en) 2012-04-27 2016-02-15 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors.
WO2013163508A1 (en) 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
PT2943488T (pt) 2013-01-11 2018-06-12 Novartis Ag Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
US9173623B2 (en) 2013-04-19 2015-11-03 Samuel Soonho Lee X-ray tube and receiver inside mouth
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
IL275188B2 (en) 2017-12-14 2024-03-01 Univ Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
HUE062537T2 (hu) 2018-12-21 2023-11-28 Univ Strasbourg Peptidek diabetes és társult betegségek kezelésére
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
JP2025505198A (ja) 2022-02-10 2025-02-21 ノバルティス アーゲー 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8525578D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Heterocyclic compounds
JP2606735B2 (ja) * 1988-02-19 1997-05-07 石原産業株式会社 ２―アミノ―４，６―ジクロロピリミジンの製造方法
US5036153A (en) * 1989-05-11 1991-07-30 Braish Tamim F Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
PT98673B (pt) * 1990-08-15 1999-01-29 British Bio Technology Processo para a preparacao de compostos que sao antagonistas do factor de activacao de plaquetas por exemplo derivados de benzimidazole e de seus intermediarios
DE4206045A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
PT637297E (pt) * 1992-04-22 2001-01-31 Ligand Pharm Inc Compostos com selectividade para os receptores de retinoide x
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
US5795890A (en) * 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
FR2765222B1 (fr) * 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
CO5011105A1 (es) * 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
FR2790260B1 (fr) * 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
DE60005973T2 (de) * 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren

Also Published As

Publication number Publication date
ATE370931T1 (de) 2007-09-15
KR100607019B1 (ko) 2006-08-01
WO2003043985A1 (en) 2003-05-30
DE60222006T2 (de) 2008-04-30
US7183304B2 (en) 2007-02-27
EP1448523B1 (en) 2007-08-22
TW200303742A (en) 2003-09-16
KR20050044556A (ko) 2005-05-12
US20110251171A1 (en) 2011-10-13
JP2005511634A (ja) 2005-04-28
ECSP045103A (es) 2004-06-28
ES2290345T3 (es) 2008-02-16
RU2004119037A (ru) 2006-01-10
CA2463154C (en) 2012-02-14
CA2463154A1 (en) 2003-05-30
AU2002352073B8 (en) 2006-11-09
CN100429201C (zh) 2008-10-29
NO327255B1 (no) 2009-05-25
US20070135502A1 (en) 2007-06-14
AR037655A1 (es) 2004-12-01
CN101362731A (zh) 2009-02-11
CO5590897A2 (es) 2005-12-30
CN1589260A (zh) 2005-03-02
HK1068874A1 (en) 2005-05-06
RU2345983C2 (ru) 2009-02-10
IL161258A0 (en) 2004-09-27
HUP0402236A3 (en) 2010-03-29
PE20030565A1 (es) 2003-08-14
EP1448523A1 (en) 2004-08-25
US20090118160A1 (en) 2009-05-07
US20040248936A1 (en) 2004-12-09
BR0214305A (pt) 2004-10-26
NO20042147L (no) 2004-05-25
JP4171700B2 (ja) 2008-10-22
AU2002352073B2 (en) 2006-10-19
AU2002352073A1 (en) 2003-06-10
DE60222006D1 (de) 2007-10-04
MY134965A (en) 2008-01-31
ZA200402310B (en) 2005-01-05
MXPA04004869A (es) 2005-04-11
HUP0402236A2 (hu) 2005-02-28
NZ532080A (en) 2006-08-31
CN101362731B (zh) 2011-01-19
PL368637A1 (en) 2005-04-04
JP2009024001A (ja) 2009-02-05
SI1448523T1 (sl) 2008-02-29
PT1448523E (pt) 2007-11-26

Similar Documents

Publication Publication Date Title
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
LTPA2016037I1 (lt) Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
IS7471A (is) Ný efnasambönd
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
ATE368042T1 (de) Cephemverbindungen
IS8108A (is) Ný efnasambönd
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
IS7879A (is) Ný efnasambönd
IS7381A (is) Efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
IS8228A (is) Ný asetídínefnasambönd
NO20045659L (no) Forbindelser
IS7827A (is) Ný efnasambönd
IS8089A (is) Efnasambönd
EP1570847A4 (en) PHOSPHODIESTERASE 10A HEMMER
NO20025659L (no) Heterocykliske forbindelser
IS8292A (is) Ný efnasambönd
IS7833A (is) Efnasambönd með sameinaða heteróhringi
NO20031736D0 (no) Forbindelser